Singapore-Based Biotech Company Nanyang Biologics Announced $1.5 Billion Nasdaq SPAC IPO with RF Acquisition Corp II, Co-Founded in 2020 by Roland Ong & Li Hoi Yeung as Joint Laboratory Initiative Between Nanyang Technological University of Singapore (NTU) & Nanyang Biologics, Shareholders The9 Limited & Mercatus Capital Will Retain Majority of Shares in Combined Company
18th October | Hong Kong
Singapore-based biotech company Nanyang Biologics has announced a $1.5 billion Nasdaq SPAC IPO with RF Acquisition Corp II. Nanyang Biologics was co-founded in 2020 by Roland Ong & Li Hoi Yeung as a joint laboratory initiative between Nanyang Technological University of Singapore (NTU) & Nanyang Biologics. Shareholders The9 Limited & Mercatus Capital will retain majority of shares in the combined company. Nanyang Biologics – The Company is an AI-driven drug discovery and biotechnology company accelerating the future of medicine through the convergence of artificial intelligence and natural compounds. Its flagship Vecura™ AI platform, powered by the proprietary Drug-Target Interaction Graph Neural Network (DTIGN), translates vast biochemical spaces into feasible drug candidates. Anchored in Singapore, NYB is building what they believe is one of the world’s largest AI-curated natural compound libraries in collaboration with global technology leaders NVIDIA, Hewlett Packard Enterprise (HPE), and Equinix, together with leading research institutions. Its pipeline of five molecules targets high unmet needs in oncology, cardiovascular, and mental health, led by NB-A002, a first-in-class targeted therapy addressing cancers with compromised DNA Damage response (DDR). RF Acquisition Corp II – RFAI is a blank check company incorporated as a Cayman Islands corporation whose business purpose is to effect a merger, capital stock exchange, asset acquisition, stock purchase, reorganization, or similar business combination with one or more businesses. While RFAI may pursue an initial business combination target in any business, industry, or geographic location, it intends to focus its search on businesses in Asia within the deep technology sector, including artificial intelligence, quantum computing, and biotechnology. RFAI was incorporated in 2024 and is based in Singapore.
“ Singapore-Based Biotech Company Nanyang Biologics Announced $1.5 Billion Nasdaq SPAC IPO with RF Acquisition Corp II, Co-Founded in 2020 by Roland Ong & Li Hoi Yeung as Joint Laboratory Initiative Between Nanyang Technological University of Singapore (NTU) & Nanyang Biologics, Shareholders The9 Limited & Mercatus Capital Will Retain Majority of Shares in Combined Company “
![](https://www.caproasia.com/wp-content/uploads/2025/08/Air-Charter-Service-728x90-1.png")
Singapore-Based Biotech Company Nanyang Biologics Announced $1.5 Billion Nasdaq SPAC IPO with RF Acquisition Corp II, Co-Founded in 2020 by Roland Ong & Li Hoi Yeung as Joint Laboratory Initiative Between Nanyang Technological University of Singapore (NTU) & Nanyang Biologics, Shareholders The9 Limited & Mercatus Capital Will Retain Majority of Shares in Combined Company
Caproasia Users
- Manage $20 million to $30 billion of assets
- Invest $3 million to $300 million
- Advise institutions, billionaires, UHNWs & HNWs
Caproasia Platforms | 11,000 Investors & Advisors
- Caproasia.com
- Caproasia Access
- Caproasia Events
- The Financial Centre | Find Services
- Membership
- Family Office Circle
- Professional Investor Circle
- Investor Relations Network
Monthly Roundtable & Networking
Family Office Programs
The 2026 Investment Day
- March - Hong Kong
- March - Singapore
- April - Hong Kong
- April - Singapore
- July - Hong Kong
- July - Singapore
- Sept- Hong Kong
- Sept - Singapore
- Oct- Hong Kong
- Nov - Singapore
- Visit: The Investment Day | Register: Click here
Caproasia Summits
- The Institutional Investor Summit
- The Investment / Alternatives Summit
- The Private Wealth Summit
- The Family Office Summit
- The CEO & Entrepreneur Summit
- The Capital Markets Summit
- The ESG / Sustainable Investment Summit
